We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 17.00 (1.03%)
Spread: 0.50 (0.03%)
Open: 1,650.00
High: 1,677.00
Low: 1,646.00
Prev. Close: 1,653.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Brexit turbo-charges UK risk premia

Thu, 10th Sep 2020 09:53

Welcome to the home for real-time coverage of European equity markets brought to you by Reuters
stocks reporters. You can share your thoughts with Joice Alves (joice.alves@thomsonreuters.com)
and Julien Ponthus (julien.ponthus@thomsonreuters.com) in London and Danilo Masoni and Stefano
Rebaudo (stefano.rebaudo@thomsonreuters.com) in Milan.

BREXIT TURBO-CHARGES UK RISK PREMIA (0850 GMT)

Risk premia on UK assets are rising and will continue to do so as investors fear a messy
divorce with the European Union when Britain finally disentangles at the end of the year.

The European Union could take legal action under its divorce treaty with Britain if today’s
emergency talks do not reassure Brussels sufficiently that a proposed new British law will not
break previously agreed commitments.

An ABN Amro research note recalls that, inside the bond bank index, NatWest Group
over the last seven days staged "the largest underperformance, with their bail-in senior bonds
moving over 30bps wider."

Other names, such as Lloyds and Barclays have only performed a few basis
points better while HSBC, Santander UK and Standard Chartered have suffered a
20 basis points hit.

ABN Amro analysts anticipate that the Brexit negotiations will continue to produce negative
headlines with little achieved in the forthcoming weeks. "UK risks premiums are likely to stay
elevated for the remainder of this year," they say.

The bank index is at 79 basis points (bps) above the swap, roughly 29 bps wider than before
the coronavirus crisis and 158 bps tighter than the pandemic highs experienced in March.

(Stefano Rebaudo)

*****

OPENING SNAPSHOT: EUROPE WAVERS BEFORE THE ECB (0725 GMT)

We're off to an uncertain start in Europe this morning with investors awaiting for the ECB
to provide fresh direction with hints of more stimulus to soften the strength of the euro
against the dollar.

Major regional benchmarks were down slightly, following mild initial gains. The STOXX 600 is
last down 0.15%.

Pandemic-hit travel and leisure stocks are up 0.7% with British Airways owner IAG
up over 2% after launching a fully underwritten 2.7 billion euros capital increase to beef up
its balance sheet.

Games Workshop is up an outstanding 18% after saying trading in the three months to
end August topped its expectations.

UK listed housebuilders are doing well after an upbeat RICS survey showed that the
post-lockdown surge in the housing market intensified in August with prices hitting a 4-year
high. Taylor Wimpey and Barratt are both up more than 2%.

Italy's Nexi is up 5% after a report said the payment firms and SIA are close to
clearing a major hurdle to a potential merger.

Weaker oil and basic material stocks weighed. Tech was lower too.

(Danilo Masoni)

*****

ON OUR RADAR: EURO, IAG CAP RISE AND DEALMAKING (0644 GMT)

As we said the European Central Bank's policy meeting and any signals from the central bank
about future easing measures will be the key highlight for investors today.

The euro and bond markets are likely to be most sensitive to ECB news, but we'll be
keeping an eye on stocks too, especially on rate-sensitive sectors like banks.

Besides that, on the corporate front, it doesn't look there is any earth shattering news out
there so far.

This will be the first full session for investors to digest LVMH's decision to
walk away from its planned $16 billion takeover of Tiffany. LVMH was little changed on
the news yesterday.

Airlines, which have been heavily hit by travel restrictions adopted to fight the COVID
pandemic, continue to be under pressure. British Airways owner IAG launched a heavily
discounted 2.7 billion euros capital increase to beef up its finances. The good news here is
that it's fully underwritten.

GlaxoSmithKline said the U.S health regulator approved its lung disease drug Trelegy
Ellipta for expanded use, making it the first inhaler delivering three drugs at once to be
prescribed for uncontrolled asthma in the country.

In M&A, Equinor raised $1.1 billion by selling stakes in offshore wind power
development projects to BP, while in Italy, the government said it's ready to use its
vetting "golden" powers to ensure the Milan exchange is not sold to an unacceptable bidder.

Meanwhile in France, utility Suez reiterated its opposition to Veolia’s
offer for Engie's stake in Suez, saying it undervalued Suez.

Among smaller companies, share placement are expected to put under pressure Ferroamp
, Carasent, and Kojamo.

In earnings news, an upbeat outlook from Akzo Nobel could lift its shares, while Dixons
reported a 56% drop mobile phone in the 17 weeks to end-August.

(Danilo Masoni)

*****

MORNING CALL: IT'S ECB DAY (0530 GMT)

Regardless of whether it's going to have any big impact on markets today the focus is
squarely on the European Central Bank's policy meeting.

The consensus is that rates will remain unchanged although investors expect signals from the
central bank which could possibly weaken the euro.

On the background are still worries over rising Brexit risks and possible further turbulence
in tech stocks, and it may be little surprise that following yesterday's rebound in Europe and
the U.S., futures are giving mixed signals at the moment.

The Euro STOXX 500 futures are up 0.3%, FTSE 100 futures are down 0.3% and Wall Street
futures are moving flat to slightly higher.

(Danilo Masoni)

*****

More News
26 Oct 2023 07:02

GSK HIV injection regimen gets approval in China

(Sharecast News) - GSK announced on Thursday that its majority-owned HIV specialist subsidiary ViiV has received approval from the National Medical Products Administration (NMPA) of China for an injection regimen.

Read more
25 Oct 2023 16:01

UK earnings, trading statements calendar - next 7 days

Thursday 26 October 
Bank of Ireland Group PLCTrading Statement
Bloomsbury Publishing PLCHalf Year Results
Botswana Diamonds PLCTrading Statement
C&C Group PLCHalf Year Results
e-Therapeutics PLCHalf Year Results
Financials Acquisition CorpTrading Statement
GCP Infrastructure Investments LtdTrading Statement
HarbourVest Global Private Equity LtdHalf Year Results
Hummingbird Resources PLCTrading Statement
Hunting PLCTrading Statement
Inchcape PLCTrading Statement
International Personal Finance PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Renishaw PLCTrading Statement
Standard Chartered PLCQ3 Results
Unilever PLCTrading Statement
WPP PLCTrading Statement
Friday 27 October 
International Consolidated Airlines Group SAQ3 Results
NatWest Group PLCQ3 Results
Monday 30 October 
Airtel Africa PLCHalf Year Results
Computacenter PLCTrading Statement
Glencore PLCTrading Statement
HSBC Holdings PLCQ3 Results
Lok'n Store Group PLCFull Year Results
Pearson PLCTrading Statement
Tuesday 31 October 
BP PLCQ3 Results
Coca-Cola HBC AGTrading Statement
Elementis PLCTrading Statement
essensys PLCFull Year Results
Georgia Capital PLCQ3 Results
Grit Real Estate Income Group LtdFull Year Results
RHI Magnesita NVTrading Statement
Spectris PLCQ3 Results
TP ICAP Group PLCTrading Statement
UP Global Sourcing Holdings PLCFull Year Results
Wednesday 1 November 
Asos PLCFull Year Results
Aston Martin Lagonda Global Holdings PLCQ3 Results
Beximco Pharmaceuticals LtdFull Year Results
GSK PLCQ3 Results
Next PLCTrading Statement
Smurfit Kappa Group PLCTrading Statement
Weir Group PLCTrading Statement
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
25 Oct 2023 09:35

GSK says RSV jab shows promising response in adults aged 50 to 59

(Alliance News) - GSK PLC on Wednesday said a trial found its respiratory syncytial virus vaccine Arexy delivered an immune response in adults aged 50 to 59.

Read more
25 Oct 2023 07:27

GSK hails success in US RSV vaccine trial

(Sharecast News) - Pharma giant GSK has announced positive preliminary results from a trial of its Arexvy vaccine to treatment respiratory syncytial virus (RSV) disease for a younger patient population in the US.

Read more
16 Oct 2023 08:09

TOP NEWS: GSK receives positive EU opinion on Jemperli for cancer

(Alliance News) - GSK PLC on Monday said its monoclonal antibody Jemperli is closer to becoming the first new frontline treatment option in the EU in decades for a certain form of endometrial cancer.

Read more
16 Oct 2023 07:44

LONDON BRIEFING: Hipgnosis pulls interim dividend on lower royalties

(Alliance News) - The FTSE 100 is likely to open higher on Monday, benefitting from higher oil and gas prices, while fears of escalating regional conflict in the Middle East damp risk sentiment elsewhere.

Read more
16 Oct 2023 07:16

GSK nears green light for Jemperli usage in Europe

(Sharecast News) - Pharma giant GSK has announced that European experts recommended the approval of its Jerperli drug for the treatment of a specific type of endometrial cancer - paving the way for marketing authorisation by the continent's regulatory body.

Read more
11 Oct 2023 11:51

GSK settles California Zantac lawsuit

(Sharecast News) - GSK has agreed to settle another lawsuit concerning its discontinued heartburn treatment Zantac, the drugs giant confirmed on Wednesday.

Read more
11 Oct 2023 09:17

LONDON BROKER RATINGS: JPMorgan raises Croda; Berenberg cuts Atalaya

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
11 Oct 2023 08:51

LONDON MARKET OPEN: FTSE 100 higher; Travis Perkins warns on profit

(Alliance News) - Stock prices in London opened largely higher on Wednesday as market mood remained resilient, despite the continuing conflict in the Middle East, amid a softening of rhetoric from the US central bank.

Read more
11 Oct 2023 08:36

TOP NEWS: GSK reaches settlement for Zantac litigation in California

(Alliance News) - GSK PLC on Wednesday said that it has reached a confidential settlement in the Cantlay/Harper case, which alleged that the firm's heartburn medication can cause cancer.

Read more
11 Oct 2023 07:47

LONDON BRIEFING: Stocks lower; GSK settles Zantac case in California

(Alliance News) - Stocks in London are set to open lower on Wednesday as investor looked ahead to the release of the US Federal Reserve's September meeting minutes later in the day.

Read more
9 Oct 2023 08:16

TOP NEWS: GSK inks agreement with Zhifei to promote shingles vaccine

(Alliance News) - GSK PLC on Monday said it has reached an exclusive agreement with Chongqing Zhifei Biological Products Ltd to co-promote its shingles vaccine, Shingrix, in China.

Read more
9 Oct 2023 07:42

LONDON BRIEFING: Metro Bank secures deal to shore up finances

(Alliance News) - Stocks in London are set to open higher on Monday as interest rate expectations held steady despite Friday's bumper US nonfarm payrolls report.

Read more
9 Oct 2023 07:20

GSK inks deal to promote shingles vaccine in China

(Sharecast News) - GSK has entered into a new exclusive vaccine partnership in China that will extend the availability of its shingle vaccine Shingrix, which will see the UK-listed group generate £2.5bn over the next three years.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.